Drug Trial Radar · NCT02040792
A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Feb 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
355
Actual
Start
May 2014
Primary completion
Jul 2014
Study completion Aug 2014
Sponsor
- Lead sponsor
- Mylan Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Theravance Biopharma
- First posted
- Jan 20, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated the safety and efficacy of four doses of TD-4208 and a placebo product when administered once daily for 28 days using a jet nebulizer to patients with moderate to severe chronic obstructive pulmonary disease.
Conditions
- COPD
Interventions
TD-4208Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Trough FEV1 (Forced Expiratory Volume in One Second)Time frame: Baseline to 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Upstate Pharmaceutical Research
Greenville, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.